We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Citalopram vs Clomipramine vs Placebo in Recurrent Depression

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: April 11, 2012
Last Update Posted: April 11, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Danish University Antidepressant Group
Information provided by (Responsible Party):
University of Aarhus
citalopram and clomipramine are better than placebo in preventing new episodes of depression in patients with recurrent depression

Condition Intervention
Depression Drug: Citalopram Drug: Clomipramine Drug: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by University of Aarhus:

Primary Outcome Measures:
  • 2 Hamilton Depression Rating Scale scores of at least 16 with one weeks interval or initiation of another antidepressant treatment [ Time Frame: 2 years of follow-up ]

Secondary Outcome Measures:
  • Study termination due to adverse event or non-compliance [ Time Frame: 2 years of follow-up ]

Enrollment: 59
Study Start Date: October 1997
Study Completion Date: September 2007
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: citalopram
Drug: Citalopram
Active Comparator: clomipramnine
Drug: Clomipramine
Placebo Comparator: placebo
Drug: placebo


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with recurrent depression
  • Sustained response achieved (3 consecutive monthly ratings at the HDS below 13)after a treatment requiring index episode

Exclusion Criteria:

  • Contraindications to study medications
  • Pregnancy
  • Substance abuse
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: University of Aarhus
ClinicalTrials.gov Identifier: NCT01575158     History of Changes
Other Study ID Numbers: DUAG-5
First Submitted: April 10, 2012
First Posted: April 11, 2012
Last Update Posted: April 11, 2012
Last Verified: April 2012

Additional relevant MeSH terms:
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Antidepressive Agents, Tricyclic